Clinical Study
Urinary Eicosanoid Metabolites in HIV-Infected Women with Central Obesity Switching to Raltegravir: An Analysis from the Women, Integrase, and Fat Accumulation Trial
Table 2
Urinary eicosanoid levels- absolute and 24-week changes, by study arm.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Values shown are median (interquartile range). F2-IsoP = F2-isoprostanes; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PGE-M = prostaglandin E2 metabolite; PGI-M = prostacyclin metabolite; RAL = raltegravir; TxB2 = thromboxane B2. |